Page 6 - Pharma Stocks

This pharma stock has zoomed over 10,000% in 96 trading days

Orchid Pharma shares were locked in the upper circuit for the 96th straight trading day

New launches, market share gains to sustain Gland Pharma's sales trajectory

Earnings are expected to grow over 25 per cent over the next two years

Pharma stocks may hold ground as volatility grips global markets

The Nifty Pharma index was down 1.76 per cent on Friday compared to a 568-point or nearly 3.8 per cent slide in the Nifty50 on weak global cues

Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5%

Among individual stocks, Lupin zoomed 3.4 per cent in the intra-day trade and hit a high of Rs 1,060, Sun Pharmaceuticals advanced 2 per cent, and Dr Reddy's Labs gained 1.7 per cent.

Weak Q3 show, margin pressures to keep Sanofi stock under pressure

Growth led by power brands and new launches could recover as pandemic impact wanes

Weak Q3, downgrades to keep Bayer CropScience stock under pressure

Given the focus on volume growth and price cuts margin pressures may remain

Apollo Hospitals to step up pharmacy, retail biz, eyes Rs 10,000 cr revenue

Core hospital segment too is looking up on the back of rise in occupancies, footfalls

Why pharma stocks are underperforming despite Rs 2.23 trn Budget allocation

Much of the increase in this year's Budget allocation for health and well-being is attributed to expenditure set aside for Covid-19 vaccination

Alembic Pharma extends decline on mixed December quarter results

Motilal Oswal Securities said Alembic Pharma missed Q3FY21 earnings estimate, weighed by lower-than-expected sales in the US

New product launches to drive growth for Lupin, US business a key trigger

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

Apollo Hospitals opens QIP with floor price of Rs 2,508.58 a share

Sources said that the hospital chain is targeting large Domestic Mutual Funds, Sovereign Funds

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Limited near term gains for Syngene International stock in pharma space

Sharp re-rating has turned the stock into the most expensive in the pharma space

Gland Pharma's growth trajectory to remain elevated in medium term

Margin expansion to support profits, clean regulatory track record to help sustain growth journey

Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%

Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE

Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis and Novel transaction has been resolved amicably to the satisfaction of all parties.

Chronic portfolio may help Cipla sustain growth outperformance in near term

Margin gains in the September quarter too are expected to continue

Pharma shares in focus; Divi's Labs hits new high, Gland Pharma zooms 20%

Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE Healthcare index were up in the range of 4 per cent to 5 per cent on the BSE

'Banking sector a good long-term bet despite expensive valuation'

The market expects a strong bounce in earnings growth in FY22 with a growth of more than 30 per cent on a YoY basis.

IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers

On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the worst returns.